Skip to main content
. 2023 May 22;15(10):2860. doi: 10.3390/cancers15102860

Figure 2.

Figure 2

EpCAM-CD3 CrossMab KIH antibody specifically binds to EpCAM-positive cells and T cells, kills EpCAM-positive target cells, and induces IFN-gamma secretion with T cells. (A) FACS shows binding of bispecific antibody to EpCAM-positive Lovo cells and to T cells. (B) Real-time cytotoxicity (RTCA) assay demonstrates killing of EpCAM-positive Lovo cells by EpCAM CrossMab KIH-CD3 antibody with T cells, in a dose-dependent manner. (C) EpCAM CrossMab KIH-CD3 antibody induces IFN-gamma secretion by T cells against EpCAM-positive cells. There was no induction of IFN-gamma secretion against EpCAM-negative Colo741 cells. * p < 0.05, Student’s t-test IFN-gamma secretion against Lovo cells versus Colo741 cells.